The association between cancer cells and normal host side factors are thought to be important in promoting cancer progression and metastasis. Herein, we focused on the clinicopathologic significance of CD47 gene expression in BM and PB of breast cancer.
Introduction
The numerous efforts for breast cancer research and care have improved early detection and treatment. However, breast cancer prevalence and mortality still maintain a high level every year; the prevention and therapy of breast cancer among Japanese women is a crucial public health concern. The most recent statistics for Japan document over 55,000 cases per year (1) with a mortality surpassing 12,000 per year (2). Even after apparently successful localized treatments, there are long-term risks of recurrence and metastasis. To evaluate the post-surgical risk of recurrence of breast cancer, mammography, echogram, CT, and MRI are utilized for diagnostic imaging, and CEA, CA15-3 and NCC-ST439 are evaluated in peripheral blood (PB) as tumor markers.
However, the long-term risk of relapse is largely due to clinically occult microrecurrences and micrometastases that are currently beyond detection by current conventional screening strategies. Therefore, it is important to exploit novel tumor markers that could predict recurrence and metastasis with greater reliability. Recent studies showed that CD47 specifically inhibits phagocytosis, and that there was a significant correlation between gene expression of CD47 and leukemia, hematopoietic stem cells, and tumor-initiating cells of bladder cancer (5) (6) (7) . It can be inferred from the association between CD47 and cancer stem cells that ITC would elude the immune system by taking advantage of activation and initiation of CD47's signal transduction cascade, resulting in inhibition of phagocytosis.
CD47 was originally identified in association with the integrin α v β 3 (hence its alternative name 'integrin-associated protein' [IAP] ). It is also a member of the Ig superfamily, possessing a V-type Ig-like extracellular domain, five putative membranespanning segments, and a short cytoplasmic tail (8) . CD47 appears to carry out several functions. For instance, CD47 functions as a marker of "self" on murine red blood cells.
Erythrocytes lacking CD47 expression are rapidly removed from the bloodstream by splenic red pulp macrophages (9, 10) . Signal regulatory protein alpha (SIRPA), a transmembrane glycoprotein, is a novel intracellular signal transducer when it is engaged by its ligand, CD47. CD47 on normal PB red cells circumvent elimination by binding to SIRPA (10). CD47's interaction with SIRPA occurs between host-derived cells, and is mostly related to cell signaling in the immune and nervous systems (11) .
In the present study, we confirmed that high expression of CK19, a marker for ITC, had correlation with high CD47 expression. Therefore, we focused on the clinicopathologic significance of CD47 gene expression in BM and PB of breast cancer and its potential utility as a novel and specific biological marker for recurrence and/or overall survival (OS) in breast cancer patients. Investigating the characteristics of CD47 mRNA expression in BM and PB in this study, we evaluated the correlation between CD47 and clinicopathological factors in 738 breast cancer cases, and demonstrated that the magnitude of CD47 expression could be used as a new prognostic marker for recurrence and metastasis. Moreover, we found that expression of CD47 and SIRPA were correlated in BM and PB. This association has potentially important implications for clinicopathological outcome. We suggest that the correlated expression of CD47 and SIRPA represents a dynamic process involved in the progression of breast cancer cells.
This report is one of the first papers to show that a host factor in bone marrow confers prognostic importance.
MATERIALS AND METHODS

Patients
A total of 738 breast cancer patients were identified based on their pathologic diagnosis before surgery at Kyushu Cancer Center from July, 2000 to August, 2005.
Written informed consent was obtained from all patients according to the guidelines approved by the Institutional Research Board. Patients ranged in age from 24 to 89 years old, with a mean age of 55.1 years old. No patients received anti hormonal treatment, chemotherapy or radiotherapy before surgery. All patients were closely followed after surgery at regular three to six months intervals, and the follow-up periods ranged from two months to six years, with a median of 3.0 years. After surgery, all patients were clearly classified into the category of breast cancer based on the all patients had a blood test before surgery, and they were confirmed to be without inflammatory symptoms. Written informed consent was obtained from all patients. All control patients had a whole body CT examination to determine whether they had cancer and their status was confirmed by assessing tumor markers in the PB. After surgery, they were followed at regular six month intervals, and the absence of cancer was confirmed over three years following surgery. 
Sample collection
BM and PB samples were obtained from patients under anesthesia before surgery. PB samples were taken from superficial veins on the opposite side of the breast cancer, and BM samples were taken from the sternum with a 15G needle. As there was a potential for contamination by skin, BM specimens were collected with another syringe after the first two to three mL were aspirated. ISOGEN-LS (NIPPON GENE CO,. LTD, Japan) was added and mixed, stored for five min at room temperature, and were immediately frozen in liquid nitrogen and stored at -80°C until RNA extraction.
Samples from non-cancer patients were obtained with same procedure.
Cell lines
The breast cancer cell lines CRL1500, MCF7, MRK-nu1, YMB1, YMB1E, SKBR3, and MDA-MB-231 were obtained from the Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer (Tohoku University, Japan).
RNA preparation and reverse transcription
Total RNA from BM and PB was extracted from control and breast cancer patients using the ISOGEN-LS method followed by Isogen-chloroform extraction and isopropanol precipitation (12) . As described previously, cDNA was synthesized from 8.0 μg of total RNA (13).
Research. 
Statistics
For continuous variables, data were expressed as means ± standard deviation. The relationship between CD47, SIRPA mRNA expression and clinicopathological factors was analyzed using the chi-square test and Student's t-test. In addition, the data was also analyzed using the non-parametric Wilcoxon rank-sum test. Survival curves were plotted according to the Kaplan-Meier method and the generalized log-rank test was applied to compare the survival curves. Variables with a value of P < 0.05 in univariate analysis were used in a subsequent multivariate analysis using the Cox regression. All tests were analyzed using JMP 7 software (SAS version 7.0.1, SAS Institute, Inc.) and the findings were considered significant when the p-value was < 0.05.
RESULTS
Comparison between CK19 and CD47 expression
In our study, we assessed CK19 expression in BM and PB of 738 breast cancer patients with quantitative real-time RT-PCR analysis. We detected 57 CK19-positive cases in BM and 57 cases in PB. We divided patients into two groups: CK19-negative group and CK19-positive group. We then evaluated CD47 expression in the BM and PB of 738 breast cancer patients with quantitative real-time RT-PCR and compared CD47 expression with CK19 status. CD47 expression in CK19-positive group was higher than that in CK19-negative group (BM: p = 0.04, PB: p = 0.02) (Supplement figure1).
CD47 expression in BM: CK19-positive group, 1.91 ± 2.06 (mean ± SD) (CI: 1.54-2.28), CK19-negative group, 1.51 ± 1.34 (CI: 1.39-1.63). CD47 expression in PB:
High expression levels of CD47 in BM and PB of breast cancer patients
In this study, we selected 19 patients with cholecystolithiasis as control cases.
Quantitative real-time RT-PCR analysis showed higher expression of CD47 mRNA in breast cancer cases than in control cases (Fig.1a-1) . In BM, the mean expression ratio of CD47/GAPDH mRNAs in breast cancer, 1.52 ± 1.43 (mean ± SD) (CI: 1.42-1.63), was significantly higher than that in non-cancer cases, 0.80 ± 0.65 (CI: 0.49-1.11) (Wilcoxon Rank-Sum test: p = 0.033). In PB, the mean expression ratio of CD47/GAPDH mRNAs in breast cancer, 1.83 ± 1.69 (mean ± SD) (CI: 1.67-1.99), was significantly higher than that in non-cancer cases, 0.48 ± 0.49 (CI: 0.24-0.73) (p = 0.0015). In Figure 1a -2, the histogram shows the number of cases within each range of expression ratios of CD47/GAPDH. We also evaluated CD47 mRNA in 32 non-cancer patients; the results of CD47 expression were similar to that from 19 patients as normal controls (Supplement Figure 2-a) .
We assessed CD47 expression in breast cancer cell lines to determine whether the expression ratio of CD47 is affected by the number of ITC in BM or PB. Human breast cancer cell lines CRL1500, MCF7, MRK-nu1, YMB1, YMB1E, SKBR3 and MDA-MB-231 were assessed. The mean expression ratio of CD47/GAPDH mRNA was 0.24 ± 0.18 (CI: 0.07-0.40) in breast cancer cell lines, and was significantly lower than those found in the BM and PB samples of breast cancer cases. Next, we compared the CD47/GAPDH ratio of each histological type of breast cancer in BM (Fig.1b) The CD47/GAPDH expression ratio in IDC was significantly higher than in DCIS (P < 0.0001) and others (P = 0.03). Such variations in the CD47/GAPDH expression ratios were likely to be reflected in the BM of IDC, therefore we focused on the IDC subtype for subsequent analyses. Table 1 shows the results of tumor markers that were analyzed in PB samples taken before surgery. The mean values of tumor markers in breast cancer were as follows: CEA 2.01 ± 3.37 (mean ± SD); CA15-3 12.19 ± 11.19; and NCC-ST439 7.45 ± 31.50. NCC-ST439 was only slightly higher than normal levels, while the values of CEA and CA15-3 were within normal levels. As a result, these tumor markers may not be useful as biomarkers in breast cancer cases before surgery.
Comparison to tumor markers
Next, we divided breast cancer patients into two groups according to their CD47/GAPDH ratios. Thus, BM and PB values were divided into those greater or less than the median CD47/GAPDH ratio; the high expression group (n=226), and the low expression group (n=226). In both BM and PB, the mean expression ratios of CD47/GAPDH mRNAs in cancer cases were significantly higher than in control patients. Furthermore, the mean ratio of CD47/GAPDH mRNAs in the high expression group of cancer cases was three to five times higher than in non-cancer cases. However, due to lack of data from breast cancer patients, particularly Her2 scores, we limited the analysis to the 452 clinical cases in which data was complete.
Clinicopathologic significance of the CD47/GAPDH mRNA expression ratio in BM is shown in Table 2 . The incidence of triple negatives for ER, PgR and Her2 status was significantly higher (P = 0.0097) in the high expression group than in the lowexpression group. The incidence of pre-menopausal patients was significantly higher (P = 0.01) in the high expression group than in the low-expression group. The incidence of the Her2 score was significantly higher (P = 0.03) in the high-expression group than in the low-expression group. The incidence of recurrence was significantly lower (P = 0.04) in the high-expression group than in the low-expression group. Conversely, no significant differences were observed regarding age, tumor stage, lymph node metastasis, lymphatic invasion, venous invasion, distant metastasis, clinical stage, estrogen receptor and progesterone receptor.
The five year disease free survival (DFS) and OS rates in patients with high CD47/GAPDH mRNA in BM and patients with low CD47/GAPDH mRNA in BM are shown in Fig 1c. The survival difference between these two groups was statistically significant (DFS: P = 0.0035; log-rank test, OS: P = 0.015; log-rank test). The patients Table 3 . Univariate analysis revealed a significant relationship between DFS and the following factors: lymphatic invasion, lymph node metastasis, venous invasion, estrogen receptor, progesterone receptor, Her2 score and CD47 expression. Multivariate analysis indicated that the high expression ratio of CD47 was found to be an independent and significant prognostic factor for survival (P = 0.024). Univariate and multivariate analyses of clinicopathological factors affecting OS rate in BM are shown in Table 3 . Univariate analysis revealed a significant relationship between OS and the following factors: menopause, lymph node metastasis, estrogen receptor, progesterone receptor, recurrence and CD47 expression). Multivariate analysis indicated that the high expression ratio of CD47 was not an independent and significant prognostic factor for survival (P = 0.41).
The clinicopathologic factors analyzed in relation to CD47 mRNA expression in PB are shown in Table 2 . The incidence of recurrence was significantly lower (P < 0.0001) in the high-expression group than in the low-expression group. The incidence of tumor stage was significantly lower (P = 0.0011) in the high-expression group than in the lowexpression group. Conversely, no significant differences were observed regarding age, menopause, lymph node metastasis, lymphatic invasion, venous invasion, distant metastasis, clinical stage, estrogen receptor, progesterone receptor, Her2 score and ER, PgR, Her2 status. The five year DFS and OS rates in patients with high CD47 mRNA and patients with low CD47 mRNA are shown in Fig. 1d . The survival difference between these two groups was not statistically significant for DFS and OS (DFS: P = 0.18; log-rank test, OS: P=0.87; log-rank test). Univariate and multivariate analyses of clinicopathological factors affecting DFS rate in PB are shown in Table 4 . Univariate Multivariate analysis indicated that the presence of lymph node metastasis was found to be an independent and significant prognostic factor for survival (P = 0.0055). Univariate and multivariate analyses of clinicopathological factors affecting OS rate in PB are shown in Table 4 . Univariate analysis revealed a significant relationship between OS and the following factors: menopause, lymph node metastasis, estrogen receptor, progesterone receptor and recurrence. Univariate analysis indicated that the high expression ratio of CD47 was not an independent and significant prognostic factor for survival.
Correlation with SIRPA
We investigated SIRPA expression in the same breast cancer patients and controls. Figure 2 shows the correlation between CD47 expression and SIRPA expression. In cancer cell lines, CD47 expression did not correlate with SIRPA expression (Spearman correlation = 0.0319, P = 0.95) (data not shown). In control patients, CD47 expression was correlated with SIRPA in both BM and PB (BM: P < 0.0001, PB: P= 0.0044) (Fig. 2a, 2b) . In 32 non-cancer cases, CD47 expression was correlated with SIRPA in both BM and PB (BM: P = 0.004, PB: P < 0.0001) (Supplement Fig. 2-b) .
In breast cancer cases, CD47 expression is more strongly correlated with SIRPA in both BM and PB (BM: P < 0.0001, PB: P < 0.0001) (Fig.2c, 2d) .
Research. (17) . CD47 is associated with α v β 3 integrin and is implicated in the modulation of integrin functions, such as cell adhesion, phagocytosis, and cellular migration (18) (19) (20) . It is known that CD47 is a marker of "self" on red blood cells. CD47 could work as a marker of self on cancer cells, and breast cancer cells may express high levels of CD47 by themselves. Our results showed that the CD47/GAPDH expression ratio in breast cancer cell lines was significantly lower than those found in the BM and PB samples of breast cancer cases.
This may indicate that CD47 has various functions, and that the level of CD47 expression was affected by the cell environment rather than the number of cancer cells.
Therefore, the high expression of CD47 in the BM and PB of breast cancer patients may represent the characteristic appearance of breast cancer and some evidence of a cancer specific mechanism in the BM and PB of breast cancer.
Recent reports showed that CD47 plays a role in inhibiting macrophage phagocytosis of cancer stem cells and tumor-initiating cells (5) (6) (7) . In the same manner as a cancer stem cell, the cancer cell itself may circumvent immune system surveillance by expressing CD47 as a marker of self, thereby evading natural killer (NK) cells (21, 22) .
In our study, we found that high CD47 expression had a correlation with high CK19 CD47 also promotes apoptosis and the CD47 ligand thrombospondin (TSP) has been implicated as an antitumor and antimetastatic factor in breast cancer (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) . Both TSP1 and a CD47 agonist peptide (4N1K, derived from TSP1) can induce a novel form of apoptosis in transformed and activated normal T cells (34, 35) , chronic lymphocytic leukemia cells (36), erythroleukemia cells, and primary arterial smooth muscle cells (35) . We supposed that CD47 may have a role not only a marker of self but also as an inducer of apoptosis to inhibit a phagocytosis.
In the present study, the mean ratio of CD47/GAPDH mRNAs in the high expression group of cancer cases was three to five times higher than in non-cancer cases. We suggested that CD47 may be specifically expressed in BM and PB of breast cancer patients and that CD47 expression may represent an important biomarker in breast cancer patients. As a result of identification of the clinical significance of CD47 expression in BM and PB, we found that overexpression of CD47 in BM and PB correlated with the aggressiveness of breast cancer. This result might suggest that the more circulating tumor cells that express increased CD47 in BM and PB, the more the active primary immune system in inducing apoptosis in tumor cells in the circulating systems. Therefore, it is important to clarify the level of CD47 expression in BM and PB to indicate whether micrometastasis exists in the breast cancer cases. Thus, CD47 may be a novel biological marker which predicts the number of highly malignant circulating tumor cells which escape from the immune systems in breast cancer. To further characterize the function of CD47 in BM and PB, we examined SIRPA expression in the same breast cancer samples. In doing so, we obtained the novel finding that the expression of CD47 and SIRPA are markedly associated. The correlation between CD47 and SIRPA was significantly stronger in breast cancer patients than in control cases. In control cases, the CD47-SIRPA signaling system is activated in BM and in PB, reflecting homeostatic regulation in the hematopoietic system. In the breast cancer cases, carcinogenicity may promote the CD47-SIRPA cell signaling system in BM and in PB, thereby possibly promoting micrometastases. We suggest that expression of the CD47/SIRPA signal system indicates the presence of cancer-specific microenvironmental areas which support micrometastasis.
In conclusion, our data indicates that CD47 is a significant prognostic indicator for DFS, and our study is one of the first to report a host factor in BM with prognostic significance. In regard to patient care, many cases require postoperative adjuvant chemotherapy. Due to the associated adverse effects of such treatment, reliable prognostic markers for recurrence and metastasis would greatly improve patient management. We suggest that this biomarker may fill that need for enhanced patient care. 
